Matches in SemOpenAlex for { <https://semopenalex.org/work/W3156132892> ?p ?o ?g. }
- W3156132892 endingPage "8702" @default.
- W3156132892 startingPage "8692" @default.
- W3156132892 abstract "Abstract Objectives The PIRADS Steering Committee has called for “higher quality data before making evidence-based recommendations on MRI without contrast enhancement as an initial diagnostic work up,” however, recognizing biparametric (bp) MRI as a reasonable option in a low-risk setting such as screening. With bpMRI, more men can undergo MRI at a lower cost and they can be spared the invasiveness of intravenous access. The aim of this study was to assess cancer detection in bpMRI vs mpMRI in sequential screening for prostate cancer (PCa). Methods Within the ongoing Göteborg PCa screening 2 trial, we assessed cancer detection in 551 consecutive participants undergoing prostate MRI. In the same session, readers first assessed bpMRI and then mpMRI. Four targeted biopsies were performed for lesions scored PIRADS 3–5 with bpMRI and/or mpMRI. Results Cancer was detected in 84/551 cases (15.2%; 95% CI: 12.4–18.4) with mpMRI and in 83/551 cases (15.1%; 95% CI: 12.3–18.2%) with bpMRI. The relative risk (RR) for cancer detection with bpMRI compared to mpMRI was 0.99 (95% one-sided CI: > 94.8); bpMRI was non-inferior to mpMRI (10% non-inferiority margin). bpMRI resulted in fewer false positives, 45/128 (35.2%), compared to mpMRI, 52/136 (38.2%), RR = 0.92; 95% CI: 0.84–0.98. Of 8 lesions scored positive only with mpMRI, 7 were false positives. The PPV for MRI and targeted biopsy was 83/128 (64.8%) for bpMRI and 84/136 (61.8%) for mpMRI, RR = 1.05, 95% CI: 1.01–1.10. Conclusions In a PSA-screened population, bpMRI was non-inferior to mpMRI for cancer detection and resulted in fewer false positives. Key Points • In screening for prostate cancer with PSA followed by MRI, biparametric MRI allows radiologists to detect an almost similar number of prostate cancers and score fewer false positive lesions compared to multiparametric MRI. • In a screening program, high sensitivity should be weighed against cost and risks for healthy men; a large number of men can be saved the exposure of gadolinium contrast medium by adopting biparametric MRI and at the same time allowing for a higher turnover in the MRI room." @default.
- W3156132892 created "2021-04-26" @default.
- W3156132892 creator A5005890005 @default.
- W3156132892 creator A5011255815 @default.
- W3156132892 creator A5022649819 @default.
- W3156132892 creator A5031309091 @default.
- W3156132892 creator A5038474126 @default.
- W3156132892 creator A5051613366 @default.
- W3156132892 creator A5065637763 @default.
- W3156132892 creator A5066906201 @default.
- W3156132892 creator A5075302650 @default.
- W3156132892 creator A5069647830 @default.
- W3156132892 date "2021-04-23" @default.
- W3156132892 modified "2023-10-16" @default.
- W3156132892 title "Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial" @default.
- W3156132892 cites W2013085411 @default.
- W3156132892 cites W2028874508 @default.
- W3156132892 cites W2156992415 @default.
- W3156132892 cites W2159803932 @default.
- W3156132892 cites W2513664992 @default.
- W3156132892 cites W2536443940 @default.
- W3156132892 cites W2541210714 @default.
- W3156132892 cites W2735260137 @default.
- W3156132892 cites W2736990592 @default.
- W3156132892 cites W2739119600 @default.
- W3156132892 cites W2790988768 @default.
- W3156132892 cites W2793905111 @default.
- W3156132892 cites W2808116211 @default.
- W3156132892 cites W2891480757 @default.
- W3156132892 cites W2902322634 @default.
- W3156132892 cites W2903204344 @default.
- W3156132892 cites W2916348473 @default.
- W3156132892 cites W2916798133 @default.
- W3156132892 cites W2922071185 @default.
- W3156132892 cites W2923048779 @default.
- W3156132892 cites W2941679071 @default.
- W3156132892 cites W2947728671 @default.
- W3156132892 cites W3012257183 @default.
- W3156132892 cites W3027874948 @default.
- W3156132892 cites W3078614411 @default.
- W3156132892 cites W3083937543 @default.
- W3156132892 doi "https://doi.org/10.1007/s00330-021-07907-9" @default.
- W3156132892 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8523442" @default.
- W3156132892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33890152" @default.
- W3156132892 hasPublicationYear "2021" @default.
- W3156132892 type Work @default.
- W3156132892 sameAs 3156132892 @default.
- W3156132892 citedByCount "19" @default.
- W3156132892 countsByYear W31561328922021 @default.
- W3156132892 countsByYear W31561328922022 @default.
- W3156132892 countsByYear W31561328922023 @default.
- W3156132892 crossrefType "journal-article" @default.
- W3156132892 hasAuthorship W3156132892A5005890005 @default.
- W3156132892 hasAuthorship W3156132892A5011255815 @default.
- W3156132892 hasAuthorship W3156132892A5022649819 @default.
- W3156132892 hasAuthorship W3156132892A5031309091 @default.
- W3156132892 hasAuthorship W3156132892A5038474126 @default.
- W3156132892 hasAuthorship W3156132892A5051613366 @default.
- W3156132892 hasAuthorship W3156132892A5065637763 @default.
- W3156132892 hasAuthorship W3156132892A5066906201 @default.
- W3156132892 hasAuthorship W3156132892A5069647830 @default.
- W3156132892 hasAuthorship W3156132892A5075302650 @default.
- W3156132892 hasBestOaLocation W31561328921 @default.
- W3156132892 hasConcept C119857082 @default.
- W3156132892 hasConcept C121608353 @default.
- W3156132892 hasConcept C126322002 @default.
- W3156132892 hasConcept C126838900 @default.
- W3156132892 hasConcept C2775934546 @default.
- W3156132892 hasConcept C2776235491 @default.
- W3156132892 hasConcept C2780192828 @default.
- W3156132892 hasConcept C2989005 @default.
- W3156132892 hasConcept C41008148 @default.
- W3156132892 hasConcept C64869954 @default.
- W3156132892 hasConcept C71924100 @default.
- W3156132892 hasConceptScore W3156132892C119857082 @default.
- W3156132892 hasConceptScore W3156132892C121608353 @default.
- W3156132892 hasConceptScore W3156132892C126322002 @default.
- W3156132892 hasConceptScore W3156132892C126838900 @default.
- W3156132892 hasConceptScore W3156132892C2775934546 @default.
- W3156132892 hasConceptScore W3156132892C2776235491 @default.
- W3156132892 hasConceptScore W3156132892C2780192828 @default.
- W3156132892 hasConceptScore W3156132892C2989005 @default.
- W3156132892 hasConceptScore W3156132892C41008148 @default.
- W3156132892 hasConceptScore W3156132892C64869954 @default.
- W3156132892 hasConceptScore W3156132892C71924100 @default.
- W3156132892 hasFunder F4320321491 @default.
- W3156132892 hasFunder F4320322581 @default.
- W3156132892 hasFunder F4320323368 @default.
- W3156132892 hasIssue "11" @default.
- W3156132892 hasLocation W31561328921 @default.
- W3156132892 hasLocation W31561328922 @default.
- W3156132892 hasLocation W31561328923 @default.
- W3156132892 hasLocation W31561328924 @default.
- W3156132892 hasOpenAccess W3156132892 @default.
- W3156132892 hasPrimaryLocation W31561328921 @default.
- W3156132892 hasRelatedWork W1557094818 @default.
- W3156132892 hasRelatedWork W1755711892 @default.
- W3156132892 hasRelatedWork W2075763133 @default.